Written Authority Required Drugs
Some Pharmaceutical Benefits Scheme (PBS) subsidised medicines need written authority approval from us before they can be prescribed.
Because of their clinical use or other special features, applications for authority approvals are made to us in writing. This includes a number of Complex Authority Required (CAR) drugs. The medicine won’t be funded without authority approval, and retrospective approval isn't allowed.
To apply for approval to prescribe a written authority required drug you must:
- send us the completed and signed PBS authority application, supporting information and authority prescription by mail or electronic upload through HPOS, and
- indicate on the authority prescription form if the approved prescription should be returned to the provider or the patient
Hospital authority form
Public hospital medical providers must use our Application for a hospital authority to supply pharmaceutical benefits and/or highly specialised drugs form or a form approved by us to apply for an authority approval.
If the medical provider is prescribing CAR HSDs in a public hospital participating in the pharmaceutical reforms, the prescriber can use the Public Hospital Prescription form.
Private hospital medical providers can use their own personalised PBS prescription pads for CAR HSD items.
When approved, the authority prescription form is stamped with CAR approval and returned by mail to the provider or patient as indicated on the form.
If the application is approved by phone, enter the relevant authority approval number on the authority prescription provided by us. Phone authority approval numbers start with Z, CARZ or TRZZ and are followed by 4 digits and 2 letters. For example, Z1234AB or CARZ1234AB or TRZZ1234AB.
Authority-approved CAR HSDs and PBS trastuzumab for early-stage breast cancer can be dispensed:
- by a public hospital or community pharmacy for public hospital items, and
- by a private hospital or community pharmacy for private hospital items
If the wrong PBS item code is claimed, PBS Online returns a warning. The claim won't be paid if the wrong PBS item code is dispensed and claimed.
The approved CAR HSD authority prescription has the approved PBS item code written on it and stamped as either a public hospital PBS item or private hospital PBS item.
The approved PBS trastuzumab authority prescription is stamped and endorsed and can be dispensed by a public hospital, private hospital or community pharmacy.
Dispensing repeats from public hospital pharmacies
Repeats on CAR HSDs and PBS trastuzumab for breast cancer can be dispensed up to the maximum number approved by us and shown on our authority approval.
Use the authority prescription number to identify repeats on hospital pharmacy records.
The patient contribution is the same as other HSDs.
Public hospital claim forms must include:
- item code
- hospital provider number
- original supply or repeat number
- supply date
- packs dispensed, and
- Human Services prescription authority number printed on the authority prescription or hospital prescription
Drug, program or condition
The PBS subsidises blinatumomab, dasatinib, imatinib mesilate and ponatinib for patients with acute lymphoblastic leukaemia (ALL).
The PBS subsidises aflibercept, ranibizumab and verteporfin for patients with subfoveal choroidal neovascularisation due to age-related macular degeneration.
The PBS subsidises medicines for eligible patients with Alzheimer's disease.
The PBS subsidises biological agents for patients with active ankylosing spondylitis.
The PBS subsidises eculizumab for patients with atypical haemolytic uraemic syndrome (aHUS).
The PBS subsidises azacitidine for patients with myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia.
The PBS subsidises vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).
The PBS subsidises sapropterin for patients with tetrahydrobiopterin (BH4) deficiency.
The PBS subsidises obinutuzumab for patients with chronic lymphocytic leukaemia.
The PBS subsidises tyrosine kinase inhibitor agents for patients with chronic myeloid leukaemia (CML).
The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension.
The PBS subsidises biological agents for patients with severe refractory Crohn's disease.
The PBS subsidises TNF alfa antagonists for paediatric patients with Crohn's disease.
The PBS subsidises ivacaftor for patients aged 2 years or older with cystic fibrosis.
The PBS subsidises ranibizumab, aflibercept and dexamethasone intravitreal implants for patients with visual impairment due to diabetic macular oedema (DMO).
The PBS subsidises trastuzumab for patients with HER2-positive early breast cancer or HER2-positive locally advanced breast cancer.
The PBS subsidises mepolizumab for patients with uncontrolled severe eosinophilic asthma.
The PBS subsidises evolocumab for patients with familial homozygous hypercholesterolaemia.
The PBS subsidises tumour necrosis factor alfa antagonists for patients with complex refractory fistulising Crohn's disease.
The PBS subsidises imatinib mesilate for patients with resected primary gastrointestinal stromal tumour with high risk of recurrence.
The PBS subsidises imatinib mesilate for patients with metastatic or unresectable malignant gastrointestinal stromal tumour.
The PBS subsidises sunitinib malate for patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).
The Growth Hormone Program provides subsidised PBS treatment to eligible children under a number of categories.
The PBS subsidises brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma.
The PBS subsidises nintedanib for patients with idiopathic pulmonary fibrosis.
The PBS subsidises eltrombopag or romiplostim for patients with severe chronic immune idiopathic thrombocytopenic purpura.
The PBS subsidises biological disease-modifying antirheumatic drugs for patients with severe active juvenile idiopathic arthritis.
The PBS subsidises pertuzumab, lapatinib ditosylate, trastuzumab emtansine and trastuzumab for patients with metastatic breast cancer.
The PBS subsidises trastuzumab for patients with metastatic stage IV HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.
The PBS subsidises bortezomib, lenalidomide and pomalidomide for patients with multiple myeloma.
The PBS subsidises lenalidomide for patients with myelodysplastic syndrome classified as low risk or Intermediate-1.
The PBS subsidises ruxolitinib for patients with myelofibrosis.
The PBS subsidises modafinil and armodafinil for patients with narcolepsy.
The PBS subsidises crizotinib for patients with anaplastic lymphoma kinase, positive non-squamous type non-small cell lung cancer or a not otherwise specified type.
The PBS subsidises a range of medicines for patients with primary pulmonary and pulmonary arterial hypertension.
The PBS subsidises biological agents for patients with severe active psoriatic arthritis.
The PBS subsidises imatinib mesilate for patients with rare diseases.
The PBS subsidises ranibizumab and aflibercept for patients with visual impairment due to macular oedema secondary to retinal vein occlusion.
The PBS subsidises biological disease-modifying antirheumatic drugs for patients with severe active rheumatoid arthritis.
The PBS subsidises rituximab for patients with severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis.
The PBS subsidises omalizumab for patients aged 12 years or older with uncontrolled severe allergic asthma.
The PBS subsidises omalizumab for paediatric patients with uncontrolled severe allergic asthma.
The PBS subsidises biological agents for adult patients with severe chronic plaque psoriasis.
The PBS subsidises etanercept for patients under 18 with severe chronic plaque psoriasis.
The PBS subsidises brentuximab vedotin for eligible patients.
The PBS subsidises tocilizumab for patients with systemic juvenile idiopathic arthritis.